Accolade, Inc. (NASDAQ:ACCD) Shares Bought by EntryPoint Capital LLC

EntryPoint Capital LLC increased its holdings in Accolade, Inc. (NASDAQ:ACCD - Free Report) by 128.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 83,787 shares of the company's stock after buying an additional 47,113 shares during the period. EntryPoint Capital LLC owned about 0.10% of Accolade worth $287,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of ACCD. Pallas Capital Advisors LLC purchased a new stake in shares of Accolade during the 4th quarter worth $38,000. Mission Creek Capital Partners Inc. purchased a new stake in shares of Accolade during the third quarter valued at about $38,000. Wolverine Trading LLC purchased a new stake in shares of Accolade during the third quarter valued at about $51,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Accolade by 1,144.1% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company's stock valued at $81,000 after buying an additional 19,232 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Accolade in the 3rd quarter worth approximately $96,000. Hedge funds and other institutional investors own 84.99% of the company's stock.

Accolade Stock Performance

Shares of Accolade stock traded up $0.01 during trading on Tuesday, hitting $6.99. 691,838 shares of the company's stock were exchanged, compared to its average volume of 1,403,698. The stock has a market capitalization of $573.13 million, a price-to-earnings ratio of -3.11 and a beta of 2.18. The business has a 50-day simple moving average of $6.94 and a 200-day simple moving average of $5.01. Accolade, Inc. has a 52-week low of $3.08 and a 52-week high of $9.86. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63.

Accolade (NASDAQ:ACCD - Get Free Report) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. On average, research analysts forecast that Accolade, Inc. will post -1.2 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ACCD. Canaccord Genuity Group restated a "hold" rating on shares of Accolade in a research note on Wednesday, January 8th. William Blair cut Accolade from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, January 8th. Stifel Nicolaus restated a "hold" rating and set a $7.03 target price (down from $8.00) on shares of Accolade in a research note on Thursday, January 9th. Stephens reiterated an "equal weight" rating and issued a $7.03 price target on shares of Accolade in a research note on Wednesday, February 12th. Finally, Truist Financial downgraded Accolade from a "strong-buy" rating to a "hold" rating in a report on Friday, January 10th. Thirteen analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Accolade currently has an average rating of "Hold" and a consensus target price of $6.51.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.